Characterization of binding sites for the omega3 receptor ligands [3H]PK11195 and [3H]RO5-4864 in human brain - PubMed (original) (raw)
Comparative Study
Characterization of binding sites for the omega3 receptor ligands [3H]PK11195 and [3H]RO5-4864 in human brain
V L Rao et al. Eur J Pharmacol. 1997.
Abstract
The kinetics and pharmacology of the isoquinoline and benzodiazepine binding sites of the omega3 or peripheral-type benzodiazepine receptors were studied using the specific ligands [3H] 7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin -2-one ([3H]PK11195) and [3H]1-(2-Chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarb oxamide ([3H]RO5-4864), respectively. Binding of both ligands was saturable, reversible, displayed nanomolar affinity, and best fit to a single site model. Occipital cortex and cerebellum displayed highest and lowest densities of binding sites respectively; for both ligands. Bmax values of [3H]PK11195 were several-fold higher than that of [3H]RO5-4864 in all regions studied consistent with their binding to distinct subunits of the human peripheral-type benzodiazepine receptor heteromeric complex. However, the isoquinoline and benzodiazepine ligands were found to be mutually competitive at nanomolar concentrations suggesting allosteric interactions between these two sites. Competition binding experiments showed that the binding of both ligands was displaced by diazepam with Ki values in the nM range, and by clonazepam in the microM range. The novel peripheral-type benzodiazepine receptor ligand 2-(4-fluorophenyl)-N,N-di-n-hexyl-1H-indole-3-acetamide (FGIN1-27) displaced only [3H]PK11195 binding with high potency. Heterogeneity of the two sites is observed, manifested by their differential susceptibility towards detergents and alcohols. Histidine residue modification by diethylpyrocarbonate treatment abolished only [3H]PK11195 binding but had no effect on [3H]RO5-4864 binding. These studies demonstrate that the isoquinoline and benzodiazepine sites on the peripheral-type benzodiazepine receptor in human brain manifest many pharmacological characteristics that are distinct from each other and from rodent brain peripheral-type benzodiazepine receptors.
Similar articles
- Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies.
Le Fur G, Vaucher N, Perrier ML, Flamier A, Benavides J, Renault C, Dubroeucq MC, Guérémy C, Uzan A. Le Fur G, et al. Life Sci. 1983 Aug 1;33(5):449-57. doi: 10.1016/0024-3205(83)90794-4. Life Sci. 1983. PMID: 6308375 - Characterization of peripheral-type benzodiazepine binding sites from rat and pig pancreas.
Giusti L, Trincavelli L, Martini C, Lucacchini A. Giusti L, et al. Biochem Pharmacol. 1994 Aug 3;48(3):583-6. doi: 10.1016/0006-2952(94)90289-5. Biochem Pharmacol. 1994. PMID: 8068045 - Characterization of two classes of benzodiazepine binding sites in Schistosoma mansoni.
Noël F, Mendonça-Silva DL, Thibaut JP, Lopes DV. Noël F, et al. Parasitology. 2007 Jul;134(Pt 7):1003-12. doi: 10.1017/S0031182007002442. Epub 2007 Feb 22. Parasitology. 2007. PMID: 17316476 - Behavioural actions of Ro 5-4864: a peripheral-type benzodiazepine?
Pellow S, File SE. Pellow S, et al. Life Sci. 1984 Jul 16;35(3):229-40. doi: 10.1016/0024-3205(84)90106-1. Life Sci. 1984. PMID: 6087055 Review. - Development of ligands for the peripheral benzodiazepine receptor.
James ML, Selleri S, Kassiou M. James ML, et al. Curr Med Chem. 2006;13(17):1991-2001. doi: 10.2174/092986706777584979. Curr Med Chem. 2006. PMID: 16842193 Review.
Cited by
- Identification of Koumine as a Translocator Protein 18 kDa Positive Allosteric Modulator for the Treatment of Inflammatory and Neuropathic Pain.
Xiong B, Jin G, Xu Y, You W, Luo Y, Fang M, Chen B, Huang H, Yang J, Lin X, Yu C. Xiong B, et al. Front Pharmacol. 2021 Jun 24;12:692917. doi: 10.3389/fphar.2021.692917. eCollection 2021. Front Pharmacol. 2021. PMID: 34248642 Free PMC article. - Concentration, distribution, and influence of aging on the 18 kDa translocator protein in human brain: Implications for brain imaging studies.
Tong J, Williams B, Rusjan PM, Mizrahi R, Lacapère JJ, McCluskey T, Furukawa Y, Guttman M, Ang LC, Boileau I, Meyer JH, Kish SJ. Tong J, et al. J Cereb Blood Flow Metab. 2020 May;40(5):1061-1076. doi: 10.1177/0271678X19858003. Epub 2019 Jun 20. J Cereb Blood Flow Metab. 2020. PMID: 31220997 Free PMC article. - Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases.
Alam MM, Lee J, Lee SY. Alam MM, et al. Nucl Med Mol Imaging. 2017 Dec;51(4):283-296. doi: 10.1007/s13139-017-0475-8. Epub 2017 Mar 16. Nucl Med Mol Imaging. 2017. PMID: 29242722 Free PMC article. Review. - Brain TSPO imaging and gray matter volume in schizophrenia patients and in people at ultra high risk of psychosis: An [11C]PBR28 study.
Selvaraj S, Bloomfield PS, Cao B, Veronese M, Turkheimer F, Howes OD. Selvaraj S, et al. Schizophr Res. 2018 May;195:206-214. doi: 10.1016/j.schres.2017.08.063. Epub 2017 Oct 12. Schizophr Res. 2018. PMID: 28893493 Free PMC article. - Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.
Pike VW. Pike VW. Curr Med Chem. 2016;23(18):1818-69. doi: 10.2174/0929867323666160418114826. Curr Med Chem. 2016. PMID: 27087244 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources